Healthcare costs now outrank even rising gas prices as consumers’ top financial concern, creating an opportunity for brands to offer short-term relief while longer-term solutions take shape.
Yet many consumers still engage with their content, pushing marketers to ensure their influencer partners have credibility.
Telehealth firms switching from compounded to brand-name GLP-1s must offer stronger patient support and expand into other high-demand treatments, like hormone therapies.
The medical society is proposing policies around bans, labels, and consent rules as fake physicians erode trust and risk patient harm.
AI can outperform doctors at some clinical tasks, but narratives overstating the tech’s advantages in patient care could erode physician trust.
More than half (53%) of patient groups view US drugmakers favorably, an 8-point drop since last year, tied to funding and engagement cuts.
FDA head Marty Makary is likely to be fired. While pharma’s relationship with him has been uneven, drugmakers may be even more concerned about Kennedy’s influence over his successor.
Google Health app will use device data and medical records to deliver health insights, intensifying competition among consumer health wearables and AI tools.
Fake health ads are flooding Facebook, meaning marketers must help consumers spot red flags like fake urgency, bogus logos, and so-called miracle cures.
Novo beat Q1 expectations thanks to Wegovy pill buzz as Lilly readies rival Foundayo, setting up weight loss drugs’ next ad showdown.
As more consumers turn to AI for health advice, embedded clinical tools aim to build trust where confidence remains low.
Like other big health insurers, CVS is exiting unprofitable markets while trimming members—a playbook to earn Wall Street approval as patients scramble for new coverage.
Pennsylvania argues in a new lawsuit that Character.AI’s “psychiatrist” bots cross into illegal practice, not just risky advice.
Nearly 60% value mental health more this year than 5 years ago, but cost and access hurdles prevent them from getting medical care.
Pharma’s new D2C sites can reduce barriers to care and treatment, but brands boost awareness of their platforms to drive adoption.
Unless Congress codifies drug pricing deals, TrumpRx risks serving more as political optics than a driver of meaningful patient affordability.
Doctors guide consumers’ clinical health decisions, but AI and influencers more often steer daily health habits.
The move could curb telehealth’s copycat obesity drugs and steer patients back to branded options.
Near-universal AI adoption in healthcare is approaching. Now organizations want their experiments to prove ROI.
Health benefits leaders often fail to inform workers about Rx savings options because opaque PBM contracts create confusion, driving the rise of more transparent, direct-to-employer pharma models.